THE EVOLVING ROLE OF IMMUNOTHERAPY IN EARLY STAGE AND ADVANCED/ METASTATIC TRIPLE NEGATIVE BREAST CANCER

August 26, 2021

This presentation will examine the evolving role of immunotherapy in early stage and advanced metastatic triple negative breast cancer including the evidence for regimens in the management of each as well as current biomarkers.

Learning Objectives

  • Examine the evidence for immunotherapy regimens in the management of triple negative breast cancer.
  • Examine the evidence for immunotherapy regimens in the management of advanced stage triple negative breast cancer.
  • Examine the current biomarkers in breast cancer predicting immunotherapy efficacy.
Course summary
Available credit: 
  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)™
Registration Opens: 
08/26/2021
Registration Expires: 
08/25/2022
Activity Starts: 
08/26/2021 - 12:30pm EDT
Activity Ends: 
08/26/2021 - 1:30pm EDT
Add to calendar: 
Rating: 
0
Durham, NC 27703
United States

Available Credit

  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)™
Please login or register to take this course.